Frevecitinib for Severe Asthma

(PANAIRAMA Trial)

This trial tests Frevecitinib, a new drug, to evaluate its effectiveness and safety for people with severe asthma. It targets individuals who continue to experience symptoms despite using medium to high doses of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA). Participants will join one of several groups, each receiving a different dose of Frevecitinib or a placebo (an inactive substance). Suitable candidates have had asthma for at least a year and experience frequent asthma attacks despite current treatments. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of people.

The trial requires that you continue your current asthma medications, like medium to high dose ICS/LABA, as they must be stable before and during the trial. However, you cannot use certain medications like oral corticosteroids or immunosuppressive drugs during the study.

Research has shown that frevecitinib, a new treatment for asthma, was safe in earlier studies. In Phase 1b trials, this inhaled medicine reduced airway inflammation with minimal impact on the rest of the body. This indicates it is generally well-tolerated when used correctly. By targeting lung problems directly, the drug lowers the risk of side effects elsewhere in the body. These findings provide promising safety evidence for those considering joining a trial.¹²³⁴⁵

Researchers are excited about Frevecitinib for severe asthma because it offers a novel approach compared to standard treatments like inhaled corticosteroids and bronchodilators. Frevecitinib works by targeting specific pathways involved in inflammation, potentially providing more precise control over asthma symptoms. This targeted action could lead to improved outcomes for patients who don't respond well to existing therapies. Additionally, the study is exploring different dosages, which may help tailor treatments to individual needs, enhancing both effectiveness and safety.

Research has shown that Frevecitinib, an inhaled treatment, could benefit people with severe asthma. Early studies found that it reduces airway swelling, a major issue in asthma, while having fewer effects on the rest of the body. In these studies, patients experienced less airway swelling, indicating potential for improved breathing and fewer asthma attacks. The treatment targets specific lung areas crucial in asthma. Although more research is needed, these early results offer hope for those whose asthma isn't well-managed by regular treatments.¹²³⁴⁶